Evidence map›Paper›PMID 33627213›Full record

ArticleZhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics2021

[Clinical effect of multicenter multidisciplinary treatment in children with renal malignant tumors].

Ze-Xi Yin, Xiang-Ling He, Jun He, Xin Tian, Cheng-Guang Zhu, Ke-Ke Chen, Run-Ying Zou, Ya-Lan You, Xin-Ping Jiang, Wen-Fang Tang and 3 more

Open access · greenAbstract readMulticenter Study
In one paragraph

Article in Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Ze-Xi YinDepartment of Hematology and Oncology, First Affiliated Hospital of Hunan Normal University/Children's Medical Center of Hunan Provincial People's Hospital, Changsha 410005, China.
Xiang-Ling HeDepartment of Hematology and Oncology, First Affiliated Hospital of Hunan Normal University/Children's Medical Center of Hunan Provincial People's Hospital, Changsha 410005, China.
Jun He
Xin TianDepartment of Hematology and Oncology, First Affiliated Hospital of Hunan Normal University/Children's Medical Center of Hunan Provincial People's Hospital, Changsha 410005, China.
Cheng-Guang ZhuDepartment of Hematology and Oncology, First Affiliated Hospital of Hunan Normal University/Children's Medical Center of Hunan Provincial People's Hospital, Changsha 410005, China.
Ke-Ke ChenDepartment of Hematology and Oncology, First Affiliated Hospital of Hunan Normal University/Children's Medical Center of Hunan Provincial People's Hospital, Changsha 410005, China.
Run-Ying ZouDepartment of Hematology and Oncology, First Affiliated Hospital of Hunan Normal University/Children's Medical Center of Hunan Provincial People's Hospital, Changsha 410005, China.
Ya-Lan YouDepartment of Hematology and Oncology, First Affiliated Hospital of Hunan Normal University/Children's Medical Center of Hunan Provincial People's Hospital, Changsha 410005, China.
Xin-Ping Jiang
Wen-Fang TangDepartment of Hematology and Oncology, First Affiliated Hospital of Hunan Normal University/Children's Medical Center of Hunan Provincial People's Hospital, Changsha 410005, China.
Min-Hui ZengDepartment of Hematology and Oncology, First Affiliated Hospital of Hunan Normal University/Children's Medical Center of Hunan Provincial People's Hospital, Changsha 410005, China.
Zhi-Jun HuangDepartment of Hematology and Oncology, First Affiliated Hospital of Hunan Normal University/Children's Medical Center of Hunan Provincial People's Hospital, Changsha 410005, China.
An-Qi YaoDepartment of Hematology and Oncology, First Affiliated Hospital of Hunan Normal University/Children's Medical Center of Hunan Provincial People's Hospital, Changsha 410005, China.
Hunan Normal University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo study the long-term clinical effect of multicenter multidisciplinary treatment (MDT) in children with renal malignant tumors.

methodsA retrospective analysis was performed on the medical data of 55 children with renal malignant tumors who were diagnosed and treated with MDT in 3 hospitals in Hunan Province from January 2015 to January 2020, with GD-WT-2010 and CCCG-WT-2016 for treatment regimens. A Kaplan-Meier survival analysis was used to analyze the survival of the children.

resultsOf the 55 children, 10 had stage I tumor, 14 had stage Ⅱ tumor, 22 had stage Ⅲ tumor, 7 had stage IV tumor, and 2 had stage V tumor. As for pathological type, 47 had FH type and 8 had UFH type. All children underwent complete tumor resection. Of the 55 children, 14 (25%) received preoperative chemotherapy. All children, except 1 child with renal cell carcinoma, received postoperative chemotherapy. Among the 31 children with indication for radiotherapy, 21 (68%) received postoperative radiotherapy. One child died of postoperative metastasis. The incidence rate of FH-type myelosuppression was 94.4%, and the incidence rate of UFH-type myelosuppression was 100%. The median follow-up time was 21 months and the median survival time was 26 months for all children, with an overall survival rate of 98% and an event-free survival rate of 95%.

conclusionsMulticenter MDT has the advantages of high success rate of operation and good therapeutic effect of chemotherapy in the treatment of children with renal malignant tumors, with myelosuppression as the most common side effects, and radiotherapy is safe and effective with few adverse events. Therefore, MDT has good feasibility, safety, and economy.

Indexed as

Kidney NeoplasmsChildFamilyHumansProgression-Free SurvivalRetrospective Studies

Identifiers

PMID33627213
PMCPMC7921527
OpenAlexW3131298341

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.